FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149900842> ?p ?o ?g. }

• W3149900842 endingPage "329" @default.
• W3149900842 startingPage "320" @default.
• W3149900842 abstract "Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies has shown high tumor response rates for patients with unresectable hepatocellular carcinoma (HCC). However, using this treatment strategy to convert initially unresectable HCC to resectable HCC was not reported.Consecutive patients with unresectable HCC who received first-line therapy with combined TKI/anti-PD-1 antibodies were analyzed. Tumor response and resectability were evaluated via imaging every 2 months (±2 weeks) using RECIST v1.1. Resectability criteria were (1) R0 resection could be achieved with sufficient remnant liver volume and function; (2) intrahepatic lesions were evaluated as partial responses or stable disease for at least 2 months; (3) no severe or persistent adverse effects occurred; and (4) hepatectomy was not contraindicated.Sixty-three consecutive patients were enrolled. Of them, 10 (15.9%) underwent R0 resection in 3.2 months (range: 2.4-8.3 months) after the initiation of combination therapy. At baseline, these 10 patients had a median largest tumor diameter of 9.3 cm, 7 had Barcelona Clinic Liver Cancer stage C (vascular invasion) disease, 2 had stage B, and 1 had stage A. Before surgery, 6 patients were evaluated as a partial response, 3 stable disease, and 1 partial response in the intrahepatic lesion but a new metastatic lesion in the right adrenal gland. Six patients (60%) achieved a pathological complete response. One patient died from immune-related adverse effects 2.4 months after hepatectomy. After a median follow-up of 11.2 months (range: 7.8-15.9 months) for other 9 patients, 8 survived without disease recurrence, and 1 experienced tumor recurrence.Combination of TKI/anti-PD-1 antibodies is a feasible conversion therapy for patients with unresectable HCC to become resectable. This study represents the largest patient cohort on downstaging role of combinational systemic therapy on TKI and PD-1 antibody for HCC." @default.
• W3149900842 created "2021-04-13" @default.
• W3149900842 creator A5002708668 @default.
• W3149900842 creator A5004612307 @default.
• W3149900842 creator A5014644502 @default.
• W3149900842 creator A5017352295 @default.
• W3149900842 creator A5029634246 @default.
• W3149900842 creator A5031371726 @default.
• W3149900842 creator A5038545320 @default.
• W3149900842 creator A5040984708 @default.
• W3149900842 creator A5042464922 @default.
• W3149900842 creator A5056338205 @default.
• W3149900842 creator A5066029512 @default.
• W3149900842 creator A5074151795 @default.
• W3149900842 creator A5079547381 @default.
• W3149900842 creator A5081994693 @default.
• W3149900842 creator A5089515440 @default.
• W3149900842 date "2021-01-01" @default.
• W3149900842 modified "2023-10-18" @default.
• W3149900842 title "Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations" @default.
• W3149900842 cites W1598702484 @default.
• W3149900842 cites W168336807 @default.
• W3149900842 cites W1755620415 @default.
• W3149900842 cites W1892595029 @default.
• W3149900842 cites W1967541992 @default.
• W3149900842 cites W1971837077 @default.
• W3149900842 cites W1994193851 @default.
• W3149900842 cites W2019607817 @default.
• W3149900842 cites W2028319026 @default.
• W3149900842 cites W2041819279 @default.
• W3149900842 cites W2042209473 @default.
• W3149900842 cites W2043882479 @default.
• W3149900842 cites W2048700210 @default.
• W3149900842 cites W2079586464 @default.
• W3149900842 cites W2096998881 @default.
• W3149900842 cites W2137869551 @default.
• W3149900842 cites W2163403599 @default.
• W3149900842 cites W2234628678 @default.
• W3149900842 cites W2235523093 @default.
• W3149900842 cites W2272984102 @default.
• W3149900842 cites W2552389495 @default.
• W3149900842 cites W2787358630 @default.
• W3149900842 cites W2808244122 @default.
• W3149900842 cites W2883115570 @default.
• W3149900842 cites W2884089708 @default.
• W3149900842 cites W2890595557 @default.
• W3149900842 cites W2897612290 @default.
• W3149900842 cites W2912335683 @default.
• W3149900842 cites W2912415842 @default.
• W3149900842 cites W2947829857 @default.
• W3149900842 cites W2953282350 @default.
• W3149900842 cites W2958829328 @default.
• W3149900842 cites W2982214764 @default.
• W3149900842 cites W2983555388 @default.
• W3149900842 cites W3004894825 @default.
• W3149900842 cites W3005059982 @default.
• W3149900842 cites W3008514541 @default.
• W3149900842 cites W3011861668 @default.
• W3149900842 cites W3015732624 @default.
• W3149900842 cites W3025022288 @default.
• W3149900842 cites W3029810811 @default.
• W3149900842 cites W3031707794 @default.
• W3149900842 cites W3034803562 @default.
• W3149900842 cites W3041263854 @default.
• W3149900842 cites W3045387409 @default.
• W3149900842 doi "https://doi.org/10.1159/000514313" @default.
• W3149900842 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8339461" @default.
• W3149900842 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34414120" @default.
• W3149900842 hasPublicationYear "2021" @default.
• W3149900842 type Work @default.
• W3149900842 sameAs 3149900842 @default.
• W3149900842 citedByCount "86" @default.
• W3149900842 countsByYear W31499008422021 @default.
• W3149900842 countsByYear W31499008422022 @default.
• W3149900842 countsByYear W31499008422023 @default.
• W3149900842 crossrefType "journal-article" @default.
• W3149900842 hasAuthorship W3149900842A5002708668 @default.
• W3149900842 hasAuthorship W3149900842A5004612307 @default.
• W3149900842 hasAuthorship W3149900842A5014644502 @default.
• W3149900842 hasAuthorship W3149900842A5017352295 @default.
• W3149900842 hasAuthorship W3149900842A5029634246 @default.
• W3149900842 hasAuthorship W3149900842A5031371726 @default.
• W3149900842 hasAuthorship W3149900842A5038545320 @default.
• W3149900842 hasAuthorship W3149900842A5040984708 @default.
• W3149900842 hasAuthorship W3149900842A5042464922 @default.
• W3149900842 hasAuthorship W3149900842A5056338205 @default.
• W3149900842 hasAuthorship W3149900842A5066029512 @default.
• W3149900842 hasAuthorship W3149900842A5074151795 @default.
• W3149900842 hasAuthorship W3149900842A5079547381 @default.
• W3149900842 hasAuthorship W3149900842A5081994693 @default.
• W3149900842 hasAuthorship W3149900842A5089515440 @default.
• W3149900842 hasBestOaLocation W31499008421 @default.
• W3149900842 hasConcept C121608353 @default.
• W3149900842 hasConcept C126322002 @default.
• W3149900842 hasConcept C141071460 @default.
• W3149900842 hasConcept C146357865 @default.
• W3149900842 hasConcept C151730666 @default.
• W3149900842 hasConcept C159110652 @default.

• next